Explore the words cloud of the PD-MIND project. It provides you a very rough idea of what is the project "PD-MIND" about.
The following table provides information about the project.
KING'S COLLEGE LONDON
|Coordinator Country||United Kingdom [UK]|
|Total cost||2˙131˙609 €|
|EC max contribution||999˙698 € (47%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-05-01 to 2022-04-30|
Take a look of project's partnership.
|1||KING'S COLLEGE LONDON||UK (LONDON)||coordinator||524˙820.00|
|2||THE UNIVERSITY OF EXETER||UK (EXETER)||participant||184˙398.00|
|3||STICHTING LYGATURE||NL (UTRECHT)||participant||100˙937.00|
|4||TECHNISCHE UNIVERSITAET DRESDEN||DE (DRESDEN)||participant||58˙125.00|
|5||UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA||IT (CHIETI)||participant||58˙125.00|
|6||Masarykova univerzita||CZ (BRNO STRED)||participant||40˙625.00|
|7||HELSE STAVANGER HF||NO (STAVANGER)||participant||16˙417.00|
|8||NORGES PARKINSONFORBUND||NO (OSLO)||participant||16˙250.00|
|9||ASTRAZENECA AB||SE (SODERTAELJE)||participant||0.00|
|10||PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG||UK (LONDON)||participant||0.00|
Parkinson Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. There is an unmet clinical need to treat Parkinson disease with mild cognitive impairment (PD-MCI). There is ample evidence from epidemiological studies as well as (pre)clinical research that Nicotinic receptors are involved in PD and cognition. Recently a clinical trial suggested that selective α7 nicotinic receptor agonist improved cognition in PD patients, as a secondary outcome measure. Hence, the main goal of PD-MIND is to show the potential of the Astrazeneca nicotinic α7 agonist AZD0328 in a randomized, placebo-controlled, international multicentre, cross-over study on cognition in people diagnosed with PD-MCI. We will assess the Attention Intensity Index composite score from the CogTrackTM system as primary outcome measure and other clinical aspects (cognition, motor symptoms) as secondary outcomes. In addition, blood, CSF and imaging biomarkers will be assessed as potential predictors of response, and as marker of target involvement. Patients (Public and Patient Involvement) and other stakeholders will be engaged from the start to allow integration of end-user perspectives in the design and execution of the project. PD-MIND will put considerably effort to disseminate and exploit clinical outcome data and biomarker results, and to sustain the partnership for subsequent phase 3 clinical studies. PD-MIND consortium consist of world-leading PD-MCI experts in the area of clinical trials, clinical coordination, project management, data management and analysis, and biomarkers. As such the consortium is well positioned to execute the proposed work and complement the EFPIA members.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PD-MIND" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PD-MIND" are provided by the European Opendata Portal: CORDIS opendata.
Bringing a prophylactic Ebola vaccine to licensureRead More
Saracatinib Trial tO Prevent FOPRead More
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitorsRead More